Wen Sherry C, Williams John V
Department of Pathology, Microbiology & Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Department of Pediatrics, University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh and University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
Clin Vaccine Immunol. 2015 Aug;22(8):858-66. doi: 10.1128/CVI.00230-15. Epub 2015 Jun 10.
Human metapneumovirus (HMPV) is a paramyxovirus discovered in 2001 in the Netherlands. Studies have identified HMPV as an important causative agent of acute respiratory disease in infants, the elderly, and immunocompromised individuals. Clinical signs of infection range from mild upper respiratory illness to more serious lower respiratory illness, including bronchiolitis and pneumonia. There are currently no licensed therapeutics or vaccines against HMPV. However, several research groups have tested vaccine candidates and monoclonal antibodies in various animal models. Several of these approaches have shown promise in animal models. This minireview summarizes the current therapies used to treat HMPV infection as well as different approaches for immunization.
人偏肺病毒（HMPV）是2001年在荷兰发现的一种副粘病毒。研究已确定HMPV是婴儿、老年人和免疫功能低下个体急性呼吸道疾病的重要病原体。感染的临床症状从轻度上呼吸道疾病到更严重的下呼吸道疾病，包括细支气管炎和肺炎。目前尚无针对HMPV的许可治疗方法或疫苗。然而，几个研究小组已在各种动物模型中测试了候选疫苗和单克隆抗体。其中一些方法在动物模型中已显示出前景。本综述总结了目前用于治疗HMPV感染的疗法以及不同的免疫方法。
